A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study
Authors:
Open Access
- 1 July 2021
- journal article
- research article
- Published by Elsevier in Kidney International Reports
- Vol. 6 (7) , 1840-1849
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Cardiovascular Toxicity of Epoetin-Alfa in Patients with Chronic Kidney DiseaseAmerican Journal of Nephrology, 2013
- High Target Hemoglobin With Erythropoiesis‐Stimulating Agents Has Advantages in the Renal Function of Non‐Dialysis Chronic Kidney Disease PatientsTherapeutic Apheresis and Dialysis, 2012
- Hypoxia-Induced Angiogenesis: Good and EvilGenes & Cancer, 2011
- Vision-Threatening Retinal Abnormalities in Chronic Kidney Disease Stages 3 to 5Clinical Journal of the American Society of Nephrology, 2011
- Reactivation of Hepatic EPO Synthesis in Mice After PHD LossScience, 2010
- Meta-analysis: Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney DiseaseAnnals of Internal Medicine, 2010
- Prevalence of Ocular Fundus Pathology in Patients with Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2010
- Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomesKidney International, 2008
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseNew England Journal of Medicine, 2006
- Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trialKidney International, 2004